세계의 재조합 단백질 시장 보고서 : 제품별, 용도별, 최종사용자별, 지역별(2025-2033년)

The global recombinant protein market size reached USD 2.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.0 Billion by 2033, exhibiting a growth rate (CAGR) of 9.55% during 2025-2033.

A recombinant protein refers to a modified or altered protein that is encoded by recombinant DNA. The recombinant DNA molecule consists of a plasmid in which the genes for a target protein are cloned. It is produced either by molecular cloning or polymerase chain reaction (PCR). Some of the common product variants include kinase proteins, human insulin, structural proteins, adhesion molecules and receptors, immune response proteins, etc. Recombinant protein is primarily utilized in the development of novel therapies for chronic and rare diseases. It finds widespread adoption in numerous biopharmaceutical companies, academic and research institutes, contract research organizations, etc.

Recombinant Protein Market Trends:

The elevating prevalence of several chronic diseases along with the increasing demand for novel treatment options is primarily driving the global recombinant protein market. In addition to this, the rising investments in the field of protein engineering and the improving focus on protein-based drug development are further augmenting the market growth. Moreover, numerous government bodies are funding R&D activities for the introduction of advanced techniques in proteomics and genomics, which are significantly impacting the global market for recombinant protein. Besides this, the advent of recombinant protein expression technology has led to the development of high-quality autoantigens that are widely used in immunotherapy procedures. Additionally, the growing requirement for recombinant proteins for accurate measurement of biomarkers in the field of drug discovery is also creating a positive outlook for the global market. Apart from this, the rising penetration of latest molecular biology approaches for biopharming to reduce proteolysis of recombinant proteins or prevent the partial or total loss of glycosylation is expected to bolster the global recombinant protein market over the forecast period.

Key Market Segmentation:

Breakup by Product:

• Antibodies
• Hormones
• Growth Factors
• Cytokines
• Others

Breakup by Application:

• Drug Discovery and Development
• Academic Research
• Biotechnology Research
• Biopharmaceutical Production
• Others

Breakup by End User:

• Pharmaceutical and Biopharmaceutical Companies
• Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organization
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abcam plc, Amgen Inc., Bio-RAD Laboratories Inc., Bio-Techne Corporation, Bps Bioscience Inc., Enzo Biochem Inc., Genscript Biotech Corporation, Merck KGaA, Novo Nordisk A/S, ProSpec-Tany TechnoGene Ltd, Sanofi S.A. and Thermo Fisher Scientific.

Key Questions Answered in This Report

• 1.What was the size of the global recombinant protein market in 2024?
• 2.What is the expected growth rate of the global recombinant protein market during 2025-2033?
• 3.What are the key factors driving the global recombinant protein market?
• 4.What has been the impact of COVID-19 on the global recombinant protein market?
• 5.What is the breakup of the global recombinant protein market based on application?
• 6.What is the breakup of the global recombinant protein market based on the end user?
• 7.What are the key regions in the global recombinant protein market?
• 8.Who are the key players/companies in the global recombinant protein market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Recombinant Protein Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Antibodies
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Hormones
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Growth Factors
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Cytokines
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Application

• 7.1 Drug Discovery and Development
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Academic Research
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Biotechnology Research
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Biopharmaceutical Production
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Pharmaceutical and Biopharmaceutical Companies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Biotechnology Companies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Academic and Research Institutes
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Contract Research Organization
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abcam plc
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Amgen Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Bio-RAD Laboratories Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Bio-Techne Corporation
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Bps Bioscience Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Enzo Biochem Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Genscript Biotech Corporation
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Merck KGaA
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Novo Nordisk A/S
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 ProSpec-Tany TechnoGene Ltd
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 Sanofi S.A.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Thermo Fisher Scientific
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis